A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CENTAURUS
- Sponsors Janssen Research & Development
- 04 Jan 2018 Planned End Date changed from 27 Nov 2020 to 20 Jul 2020.
- 12 Dec 2017 Preliminary results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2017 Results presented in a Janssen media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History